{"id":"39d316cc-181a-452c-b71c-d0a23f695ce4","companyId":"7229f667-acb1-4bee-a44e-e65653aeb565","modelName":"Evie Ring (and EvieMED)","slug":"movano-evie-ring","description":"Movano Health (NASDAQ: MOVE; led by chief executive John Mastrototaro) makes the women's-health-focused Evie smart ring, recorded in the biometric form factor, with cycle tracking and women's-health metrics as its editorial differentiator. A load-bearing entity split applies: there are two rings, the consumer Evie Ring, which tracks the menstrual cycle, sleep, energy, heart rate, blood oxygen, and mood as a general-wellness device that is not FDA-cleared, and the separate business-to-business EvieMED Ring, which received an FDA 510(k) clearance for its pulse oximeter and heart rate on December 2, 2024 for clinical trials, remote patient monitoring, and payor and pharma use, with a pivotal study showing accuracy across darker skin tones, so the clearance must not be attributed to the consumer Evie Ring. A significant financial cap-flag is the real risk here: Movano is distressed, with its SEC filings showing going-concern substantial doubt, an accumulated deficit of $160.5 million as of September 30, 2025, cash not sufficient to fund operations beyond the first quarter of 2026 without further capital or a merger, a strategic review and possible sale underway, a one-for-ten reverse stock split in October 2025 to regain NASDAQ compliance, and a $1.5 million bridge loan at an effective rate around 111.6 percent secured by the company's intellectual property that transfers to the lender if a merger fails to close, so the registry records it at commercial maturity but at risk with an active lifecycle and a re-verification flag given the volatile status. A source-drift note: a secondary article cites a stale 2024 cash figure that the SEC filings supersede with the going-concern position, and the company's market-size framing is total-addressable-market language rather than verified revenue.","formFactor":"biometric","maturityStage":"commercial","lifecycleState":"paused","supersededByModelId":null,"specs":{"notes":[{"label":"Verified (women's-health differentiator + the two-ring split)","value":"Movano Health (NASDAQ: MOVE; CEO John Mastrototaro) makes the women's-health-focused Evie Ring - the editorial differentiator (cycle tracking + women's-health metrics as primary positioning). KEY split: the consumer Evie Ring is GENERAL-WELLNESS (not cleared); the FDA 510(k) clearance (pulse oximeter + HR, Dec 2 2024) belongs to the separate B2B EvieMED Ring - do NOT attribute the clearance to the consumer Evie. A pivotal study showed accuracy across darker skin tones (Fitzpatrick)."},{"label":"FINANCIAL CAP-FLAG (going-concern - the real risk)","value":"Movano is financially DISTRESSED: SEC 10-Qs show going-concern substantial doubt, accumulated deficit $160.5M (Sep 30 2025), cash not sufficient beyond Q1 2026 without further capital or a merger; a strategic review / possible sale is underway; a 1-for-10 reverse split (Oct 2025) to regain NASDAQ compliance; a $1.5M bridge loan at ~111.6% effective rate secured by Movano's IP (transfers to the lender if a merger fails). maturity=commercial but AT-RISK; lifecycleState=active. RE-VERIFY before relying on (status volatile)."},{"label":"Cap-flag (source drift)","value":"A reverse-split secondary source cites a STALE Q3-2024 cash figure ($11.3M / '12 months runway') - the SEC 10-Qs SUPERSEDE it (going-concern, runway not beyond Q1 2026). Trust the 10-Q. '$40B market' framing is company TAM, not verified revenue."},{"label":"Re-verify 2026-06-03 (MATERIAL)","value":"Movano Health's strategic review resolved in a COMPLETED all-stock reverse merger with Corvex (closed Mar 19 2026; renamed Corvex, Inc. effective Mar 23 2026; same ticker NASDAQ: MOVE). The combined entity pivoted to AI cloud / GPU infrastructure (NVIDIA H200); legacy Movano shareholders retained <5%. Evie / Wellness Ring CONSUMER SALES are PAUSED and the healthcare assets (incl. the FDA-cleared EvieMED Ring) are being explored for sale/divestiture. A 1-for-10 reverse split occurred (~Oct 2025). lifecycleState active->PAUSED (sales paused, divestiture-pending; maturityStage left at commercial as the historical peak, per the active/retired split). Cap-flag: the divestiture is an INTENTION, not a closed transaction; a '$1B equity facility' and co-CEO appointments are conditional/reported-only."}],"specs":"TWO rings: Evie Ring (CONSUMER, women's-health-focused: menstrual-cycle tracking, sleep, energy, HR, SpO2, mood/goal trends; GENERAL-WELLNESS) + EvieMED Ring (B2B/clinical variant; FDA 510(k)-cleared pulse oximeter + HR, Dec 2 2024; for clinical trials / remote patient monitoring / payors-pharma). Company: Movano Health (NASDAQ: MOVE; CEO John Mastrototaro).","formFactor":"biometric (biometric-primary women's-health smart ring + AI; consumer general-wellness + B2B FDA-cleared variant)"},"manufacturerSerial":null,"reviewStatus":"reviewed","sources":[{"url":"https://www.prnewswire.com/news-releases/movano-health-receives-fda-clearance-for-eviemed-ring-302319677.html","title":"Movano EvieMED Ring FDA 510(k) clearance (pulse oximeter + HR; Dec 2 2024) - the B2B/clinical variant","sourceName":"Movano (PR Newswire)"},{"url":"https://www.mobihealthnews.com/news/movano-health-secures-fda-clearance-eviemed-ring","title":"Movano EvieMED FDA clearance; consumer Evie = women's-health metrics (cycle/sleep/mood/HR/SpO2)","sourceName":"MobiHealthNews"},{"url":"https://www.sec.gov/Archives/edgar/data/0001734750/000121390025110877/ea0261389-10q_movano.htm","title":"Movano 10-Q (FY2025): going-concern; accumulated deficit $160.5M; runway not beyond Q1 2026; strategic review","sourceName":"SEC EDGAR"},{"url":"https://www.corvex.ai/blog/press-release-corvex-to-go-public-in-all-stock-merger-withmovano-creating-a-pure-play-platform-for-secure-ai-infrastructure-and-high-performanceinference","title":"Corvex to go public in all-stock merger with Movano (pivot to secure AI infrastructure)","sourceName":"Corvex (IR)"},{"url":"https://www.arlnow.com/2026/03/25/va-square-based-ai-company-goes-public-after-merger-with-health-tech-firm/","title":"Va. Square AI company (Corvex) goes public after merger with Movano (closed Mar 19 2026; renamed Mar 23)","sourceName":"ARLnow"}],"aliases":["Evie Ring","EvieMED Ring","Movano Evie"],"collisionRisk":"low","reviewNote":null,"manufacturerTermForTeleop":null,"createdAt":"2026-06-03T22:46:35.456Z","updatedAt":"2026-06-04T02:39:29.584Z","jsonLd":{"@context":"https://schema.org","@type":"Product","@id":"https://registry.deploy.report/models/movano-evie-ring","url":"https://registry.deploy.report/models/movano-evie-ring","name":"Evie Ring (and EvieMED)","alternateName":["Evie Ring","EvieMED Ring","Movano Evie"],"description":"Movano Health (NASDAQ: MOVE; led by chief executive John Mastrototaro) makes the women's-health-focused Evie smart ring, recorded in the biometric form factor, with cycle tracking and women's-health metrics as its editorial differentiator. A load-bearing entity split applies: there are two rings, the consumer Evie Ring, which tracks the menstrual cycle, sleep, energy, heart rate, blood oxygen, and mood as a general-wellness device that is not FDA-cleared, and the separate business-to-business EvieMED Ring, which received an FDA 510(k) clearance for its pulse oximeter and heart rate on December 2, 2024 for clinical trials, remote patient monitoring, and payor and pharma use, with a pivotal study showing accuracy across darker skin tones, so the clearance must not be attributed to the consumer Evie Ring. A significant financial cap-flag is the real risk here: Movano is distressed, with its SEC filings showing going-concern substantial doubt, an accumulated deficit of $160.5 million as of September 30, 2025, cash not sufficient to fund operations beyond the first quarter of 2026 without further capital or a merger, a strategic review and possible sale underway, a one-for-ten reverse stock split in October 2025 to regain NASDAQ compliance, and a $1.5 million bridge loan at an effective rate around 111.6 percent secured by the company's intellectual property that transfers to the lender if a merger fails to close, so the registry records it at commercial maturity but at risk with an active lifecycle and a re-verification flag given the volatile status. A source-drift note: a secondary article cites a stale 2024 cash figure that the SEC filings supersede with the going-concern position, and the company's market-size framing is total-addressable-market language rather than verified revenue.","identifier":"39d316cc-181a-452c-b71c-d0a23f695ce4","category":"biometric","publisher":{"@id":"https://deploy.report/#organization"}}}